Overview

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A phase II study to evaluate safety, tolerability and efficacy of CS0159 in patients with PBC (Primary Biliary Cholangitis).
Phase:
Phase 2
Details
Lead Sponsor:
Cascade Pharmaceuticals, Inc